Hosted on MSN10h
GSK stays optimistic on vaccines amidst US and China woes
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
BioPharma Dive16h
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.
FiercePharma19h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...